Christian Radauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian Radauer has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Karin Hoffmann-Sommergruber
Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
33 shared publications Heimo Breiteneder
Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria
32 shared publications- Merima Bublin
Medical University of Vienna Vienna Austria
30 shared publications - Heimo Breiteneder
Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
25 shared publications Otto Scheiner
Department of Pathophysiology, Medical University of Vienna, Vienna, Austria. Fax: +43-1-40400-5130
15 shared publicationsChristof Ebner
Allergy Clinic Reumannplatz Vienna Austria
12 shared publications
Latest Publications
- Open Access
New Allergens Approved by the WHO / IUIS Allergen Nomenclature Sub‐Committee in 2021–2024 and Their Significance for Future Diagnostics, Regulation, and Research. An EAACI Task Force Report
The WHO/IUIS Allergen Nomenclature Sub‐Committee is an international body of experts that maintains the systematic nomenclature of allergenic proteins by assigning official names to newly identified allergens submitted by researchers. Here, we summarize the data on new allergens approved between 2021 and 2024. The sub‐committee assigned names to 112 new allergens with 124 isoallergens/variants as well as 26 new isoallergens/variants of previously named allergens. Most new allergens were respiratory allergens from animals (35 allergens) and plants (25) as well as food allergens from animals (22) and plants (17). Many newly identified allergens reflect globalized allergen exposure and growing research activities outside of Western countries. This is illustrated by allergens from the tropical mite Blomia tropicalis , pollen allergens from tree and weed species native to Asia, and food allergens from regionally important foods such as mango, seafood, silkworm pupae, and natto. The allergen profiles of most relevant sources are well established, but gaps in our knowledge remain, particularly regarding allergens important for populations outside of Europe and North America. The still growing number of known allergens highlights the importance of a consistent, unambiguous allergen nomenclature that evolves with clinical demands and scientific discovery and supports efforts to close existing knowledge gaps.
Open AccessNew Allergens Approved by the WHO / IUIS Allergen Nomenclature Sub‐Committee in 2021–2024 and Their Significance for Future Diagnostics, Regulation, and Research. An EAACI Task Force Report
The WHO/IUIS Allergen Nomenclature Sub‐Committee is an international body of experts that maintains the systematic nomenclature of allergenic proteins by assigning official names to newly identified allergens submitted by researchers. Here, we summarize the data on new allergens approved between 2021 and 2024. The sub‐committee assigned names to 112 new allergens with 124 isoallergens/variants as well as 26 new isoallergens/variants of previously named allergens. Most new allergens were respiratory allergens from animals (35 allergens) and plants (25) as well as food allergens from animals (22) and plants (17). Many newly identified allergens reflect globalized allergen exposure and growing research activities outside of Western countries. This is illustrated by allergens from the tropical mite Blomia tropicalis , pollen allergens from tree and weed species native to Asia, and food allergens from regionally important foods such as mango, seafood, silkworm pupae, and natto. The allergen profiles of most relevant sources are well established, but gaps in our knowledge remain, particularly regarding allergens important for populations outside of Europe and North America. The still growing number of known allergens highlights the importance of a consistent, unambiguous allergen nomenclature that evolves with clinical demands and scientific discovery and supports efforts to close existing knowledge gaps.
- Open Access
Cross‐protection of allergen immunotherapy‐induced antibodies to related allergens requires a high degree of structural identity
Background: In contrast to sublingual immunotherapy (SLIT) with recombinant Mal d 1 (rMal d 1‐SLIT), SLIT with rBet v 1 (rBet v 1‐SLIT) induced Mal d 1‐cross‐reactive antibodies without IgE‐blocking activity. To elucidate whether the development of cross‐protective IgG responses depends on the degree of molecular identity of allergens we compared the cross‐reactivity, cross‐blocking activity, and affinity of SLIT‐induced antibodies with allergens of varying amino acid sequence identities to Bet v 1 and Mal d 1, namely Cor a 1.04 (hazelnut), Pru av 1 (cherry), and Dau c 1 (carrot). Methods: Allergen‐specific antibodies were quantified by ELISA. IgE blocking was analyzed by inhibition of allergen‐induced basophil activation and IgE‐facilitated allergen‐presentation to T cells. The affinity of SLIT‐induced antibodies was studied by acidic dissociation ELISA and competition ELISA. Identical surface areas on allergens were predicted using an in‐house designed script based on structural alignments. Results: rBet v 1‐SLIT‐induced IgG antibodies cross‐reacted with all allergens except Dau c 1. rMal d 1‐SLIT‐induced antibodies predominantly cross‐reacted with Pru av 1 and displayed significantly higher IgE blocking to Pru av 1 than rBet v 1‐SLIT‐induced antibodies. rMal d 1‐SLIT‐induced IgG1 showed higher affinity to Mal d 1 and Pru av 1. Surface analysis revealed 84% identical area on Mal d 1 and Pru av 1. Furthermore, we identified two surface areas potentially containing epitopes present on these allergens and absent on Bet v 1. Conclusion: In summary, our findings suggest that a relatively high threshold of similarity is required to establish effective cross‐blocking antibodies to related allergens. Apparently, the structural identity between Bet v 1 and Mal d 1 is below this threshold. Therefore, this study may explain why immunotherapy with birch pollen allergen often fails to reduce birch pollen‐related apple allergy.
Open AccessCross‐protection of allergen immunotherapy‐induced antibodies to related allergens requires a high degree of structural identity
Background: In contrast to sublingual immunotherapy (SLIT) with recombinant Mal d 1 (rMal d 1‐SLIT), SLIT with rBet v 1 (rBet v 1‐SLIT) induced Mal d 1‐cross‐reactive antibodies without IgE‐blocking activity. To elucidate whether the development of cross‐protective IgG responses depends on the degree of molecular identity of allergens we compared the cross‐reactivity, cross‐blocking activity, and affinity of SLIT‐induced antibodies with allergens of varying amino acid sequence identities to Bet v 1 and Mal d 1, namely Cor a 1.04 (hazelnut), Pru av 1 (cherry), and Dau c 1 (carrot). Methods: Allergen‐specific antibodies were quantified by ELISA. IgE blocking was analyzed by inhibition of allergen‐induced basophil activation and IgE‐facilitated allergen‐presentation to T cells. The affinity of SLIT‐induced antibodies was studied by acidic dissociation ELISA and competition ELISA. Identical surface areas on allergens were predicted using an in‐house designed script based on structural alignments. Results: rBet v 1‐SLIT‐induced IgG antibodies cross‐reacted with all allergens except Dau c 1. rMal d 1‐SLIT‐induced antibodies predominantly cross‐reacted with Pru av 1 and displayed significantly higher IgE blocking to Pru av 1 than rBet v 1‐SLIT‐induced antibodies. rMal d 1‐SLIT‐induced IgG1 showed higher affinity to Mal d 1 and Pru av 1. Surface analysis revealed 84% identical area on Mal d 1 and Pru av 1. Furthermore, we identified two surface areas potentially containing epitopes present on these allergens and absent on Bet v 1. Conclusion: In summary, our findings suggest that a relatively high threshold of similarity is required to establish effective cross‐blocking antibodies to related allergens. Apparently, the structural identity between Bet v 1 and Mal d 1 is below this threshold. Therefore, this study may explain why immunotherapy with birch pollen allergen often fails to reduce birch pollen‐related apple allergy.
- Top Cited PapersOpen Access
- 1 March 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (S28) , e13854
EAACIMolecular Allergology User's Guide 2.0
Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE‐mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE‐mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well‐defined, highly pure molecules for component‐resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients. The first edition of the “EAACI Molecular Allergology User's Guide” (MAUG) in 2016 rapidly became a key reference for clinicians, scientists, and interested readers with a background in allergology, immunology, biology, and medicine. Nevertheless, the field of molecular allergology is moving fast, and after 6 years, a new EAACI Taskforce was established to provide an updated document. The Molecular Allergology User's Guide 2.0 summarizes state‐of‐the‐art information on allergen molecules, their clinical relevance, and their application in diagnostic algorithms for clinical practice. It is designed for both, clinicians and scientists, guiding health care professionals through the overwhelming list of different allergen molecules available for testing. Further, it provides diagnostic algorithms on the clinical relevance of allergenic molecules and gives an overview of their biology, the basic mechanisms of test formats, and the application of tests to measure allergen exposure.
- 1 March 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (S28) , e13854
Top Cited PapersOpen AccessEAACIMolecular Allergology User's Guide 2.0
Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE‐mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE‐mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well‐defined, highly pure molecules for component‐resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients. The first edition of the “EAACI Molecular Allergology User's Guide” (MAUG) in 2016 rapidly became a key reference for clinicians, scientists, and interested readers with a background in allergology, immunology, biology, and medicine. Nevertheless, the field of molecular allergology is moving fast, and after 6 years, a new EAACI Taskforce was established to provide an updated document. The Molecular Allergology User's Guide 2.0 summarizes state‐of‐the‐art information on allergen molecules, their clinical relevance, and their application in diagnostic algorithms for clinical practice. It is designed for both, clinicians and scientists, guiding health care professionals through the overwhelming list of different allergen molecules available for testing. Further, it provides diagnostic algorithms on the clinical relevance of allergenic molecules and gives an overview of their biology, the basic mechanisms of test formats, and the application of tests to measure allergen exposure.
- Open Access
- 8 August 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (8) , e12177
Pru du 1, the Bet v 1‐homologue from almond, is a major allergen in patients with birch pollen associated almond allergy
Background: Almond allergy is common and can manifest in two different forms. Primary almond allergy has been reported to be associated with sensitization to almond legumin Pru du 6. In birchendemic regions, there is a link between birch‐pollinosis which is likely based on a cross‐reactive Bet v 1 homologue, a yet unidentified allergen in almond. Therefore, we sought to identify and characterize a Bet v 1‐homologue in almond.Methods: The expression of a Bet v 1 homologue in almond kernels was confirmed by mass spectrometry. The recombinant protein was produced in Escherichia coli and its cross‐reactivity and allergenic potency was analyzed by IgE quantitative and competitive ELISA, immunoblotting and basophil histamine release using sera from 17 almond allergic patients.Results: The identified Bet v 1 homologue received the designation Pru du 1.0101. Pru du 1.0101 bound IgE from 82 % of almond allergic patients. Bet v 1 was able to inhibit IgE‐binding to rPru du 1 by 100%, while rPru du 1 inhibited IgE binding to rBet v 1 by 48%. Pru du 1.0101 activated basophils, though 100‐ to 1000‐fold higher concentrations were required for maximum activation in comparison to rBet v 1.Conclusion: Considering the strong inhibition capacity and higher allergenic potency of Bet v 1, the results provide compelling evidence for primary sensitization to Bet v 1 in case of birch pollen associated almond allergy. Combining Pru du 6 and Pru du 1 in diagnostic approaches may help to discriminate between primary and birch‐pollen associated almond allergy.
- 8 August 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (8) , e12177
Open AccessPru du 1, the Bet v 1‐homologue from almond, is a major allergen in patients with birch pollen associated almond allergy
Background: Almond allergy is common and can manifest in two different forms. Primary almond allergy has been reported to be associated with sensitization to almond legumin Pru du 6. In birchendemic regions, there is a link between birch‐pollinosis which is likely based on a cross‐reactive Bet v 1 homologue, a yet unidentified allergen in almond. Therefore, we sought to identify and characterize a Bet v 1‐homologue in almond.Methods: The expression of a Bet v 1 homologue in almond kernels was confirmed by mass spectrometry. The recombinant protein was produced in Escherichia coli and its cross‐reactivity and allergenic potency was analyzed by IgE quantitative and competitive ELISA, immunoblotting and basophil histamine release using sera from 17 almond allergic patients.Results: The identified Bet v 1 homologue received the designation Pru du 1.0101. Pru du 1.0101 bound IgE from 82 % of almond allergic patients. Bet v 1 was able to inhibit IgE‐binding to rPru du 1 by 100%, while rPru du 1 inhibited IgE binding to rBet v 1 by 48%. Pru du 1.0101 activated basophils, though 100‐ to 1000‐fold higher concentrations were required for maximum activation in comparison to rBet v 1.Conclusion: Considering the strong inhibition capacity and higher allergenic potency of Bet v 1, the results provide compelling evidence for primary sensitization to Bet v 1 in case of birch pollen associated almond allergy. Combining Pru du 6 and Pru du 1 in diagnostic approaches may help to discriminate between primary and birch‐pollen associated almond allergy.
- Open Access
- 1 May 2022
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 149 (5) , 1786-1794.e12
Isotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1
- 1 May 2022
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 149 (5) , 1786-1794.e12
Open AccessIsotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1
- Open Access
IgE‐cross‐blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1
Background: Evidence has accumulated that birch pollen immunotherapy reduces rhinoconjunctivitis to pollen of birch homologous trees. Therapeutic efficacy has been associated with IgE‐blocking IgG antibodies. We have recently shown that sera collected after 16 weeks of sublingual immunotherapy with recombinant Bet v 1 (rBet v 1‐SLIT) display strong IgE‐blocking bioactivity for Bet v 1. Here, we assessed whether rBet v 1‐SLIT‐induced IgG antibodies display cross‐blocking activity to related allergens in Fagales pollen.Methods: IgE, IgG1 and IgG4 reactivity to recombinant Bet v 1, Aln g 1, Car b 1, Ost c 1, Cor a 1, Fag s 1, Cas s 1 and Que a 1 were assessed in pre‐ and post‐SLIT samples of 17 individuals by ELISA. A basophil inhibition assay using stripped basophils re‐sensitized with a serum pool containing high Bet v 1‐specific IgE levels was established and used to assess CD63 expression in response to allergens after incubation with pre‐SLIT or post‐SLIT samples. IgG1 and IgG4 were depleted from post‐SLIT samples to assess its contribution to IgE‐cross‐blocking.Results: Sublingual immunotherapy with recombinant Bet v 1 boosted cross‐reactive IgE antibodies and induced IgG1 and IgG4 antibodies with inter‐ and intra‐individually differing reactivity to the homologs. Highly variable cross‐blocking activities of post‐SLIT samples to the different allergens were found. IgG1 and IgG4 antibodies displayed cross‐blocking activity with individual variance.Conclusions: Our mechanistic approach suggested that immunotherapy with the reference allergen Bet v 1 induces individual repertoires of cross‐reactive IgG1 and IgG4 antibodies. The cross‐blocking bioactivity of these antibodies was also highly variable and neither predictable from protein homology nor IgE‐cross‐reactivity.
Open AccessIgE‐cross‐blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1
Background: Evidence has accumulated that birch pollen immunotherapy reduces rhinoconjunctivitis to pollen of birch homologous trees. Therapeutic efficacy has been associated with IgE‐blocking IgG antibodies. We have recently shown that sera collected after 16 weeks of sublingual immunotherapy with recombinant Bet v 1 (rBet v 1‐SLIT) display strong IgE‐blocking bioactivity for Bet v 1. Here, we assessed whether rBet v 1‐SLIT‐induced IgG antibodies display cross‐blocking activity to related allergens in Fagales pollen.Methods: IgE, IgG1 and IgG4 reactivity to recombinant Bet v 1, Aln g 1, Car b 1, Ost c 1, Cor a 1, Fag s 1, Cas s 1 and Que a 1 were assessed in pre‐ and post‐SLIT samples of 17 individuals by ELISA. A basophil inhibition assay using stripped basophils re‐sensitized with a serum pool containing high Bet v 1‐specific IgE levels was established and used to assess CD63 expression in response to allergens after incubation with pre‐SLIT or post‐SLIT samples. IgG1 and IgG4 were depleted from post‐SLIT samples to assess its contribution to IgE‐cross‐blocking.Results: Sublingual immunotherapy with recombinant Bet v 1 boosted cross‐reactive IgE antibodies and induced IgG1 and IgG4 antibodies with inter‐ and intra‐individually differing reactivity to the homologs. Highly variable cross‐blocking activities of post‐SLIT samples to the different allergens were found. IgG1 and IgG4 antibodies displayed cross‐blocking activity with individual variance.Conclusions: Our mechanistic approach suggested that immunotherapy with the reference allergen Bet v 1 induces individual repertoires of cross‐reactive IgG1 and IgG4 antibodies. The cross‐blocking bioactivity of these antibodies was also highly variable and neither predictable from protein homology nor IgE‐cross‐reactivity.
- Open Access
- 1 January 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (1) , 229-238
Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity
- 1 January 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (1) , 229-238
Open AccessDevelopment of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity
- Open Access
- 1 August 2019
- Published by Elsevier in Molecular Immunology
- Vol. 112, 140-150
Fish-derived low molecular weight components modify bronchial epithelial barrier properties and release of pro-inflammatory cytokines
- 1 August 2019
- Published by Elsevier in Molecular Immunology
- Vol. 112, 140-150
Open AccessFish-derived low molecular weight components modify bronchial epithelial barrier properties and release of pro-inflammatory cytokines
- Open Access
Allergen databases—A critical evaluation
- 1 March 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 143 (3) , 1226-1229.e10
Engineering of structural variants of the major peanut allergens Ara h 2 and Ara h 6 for allergen-specific immunotherapy
- 1 March 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 143 (3) , 1226-1229.e10
Engineering of structural variants of the major peanut allergens Ara h 2 and Ara h 6 for allergen-specific immunotherapy